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With several recent FDA approvals and a strong drug pipeline, gene therapy is coming of age. With this comes 
the requirement to ensure that there are robust manufacturing processes in place in order to scale with demand 
and to make these therapies readily accessible to those who need them. However, current manufacturing 
processes for gene therapies have often been developed with limited scalability in mind and large shifts in 
technology have to take place to enable industrialization. This also has to be done while keeping costs in mind. 
Here, we will present a case study which illustrates the challenges and solutions to scale both up and 
downstream process steps required to manufacture adenovirus. After implementation of a bioreactor, the 
bioreactor scale increased 125 fold, from 0.53m2 to 66 m2. With the implementation of several scalable unit 
operations on the downstream, this took 1 day as opposed to 3 – 4 days required for the entire optimized 
process generating purified viral vector for the successfully completion of a global in vivo toxicology study. 







Figure 1 – Linear titer scalability: Process development from flatware to Manufacturing Scale 
 
